Vivos (RDGL) 10-K 25 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 22, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	VIVOS INC
Entity Central Index Key	0001449349
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 359,968
Entity Common Stock, Shares Outstanding		1,369,987,688
Trading Symbol	RDGL
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash	$ 5,494	$ 8,317
Prepaid expenses	10,992	6,711
Total Current Assets	16,486	15,028
Fixed assets, net
Other Assets:
Deposits		669
TOTAL ASSETS	16,486	15,697
Current Liabilities:
Accounts payable and accrued expenses	795,129	840,972
Related party accounts payable	38,610	57,297
Accrued interest payable	59,646	347,069
Payroll liabilities payable	11,451	85,786
Convertible notes payable, net	53,824	2,563,272
Related party promissory note		383,771
Total Current Liabilities	958,660	4,278,167
Total Liabilities	958,660	4,278,167
Commitments and contingencies
STOCKHOLDERS' DEFICIT
Common stock, par value, $0.001, 2,000,000,000 shares authorized, 1,307,565,888 and 65,695,213 issued and outstanding, respectively	1,307,566	65,695
Additional paid in capital - common stock	58,988,019	46,408,443
Accumulated deficit	(71,991,012)	(64,288,167)
Total Stockholders' Deficit	(942,174)	(4,262,470)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	16,486	15,697
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock	2,553	3,779
Additional paid in capital - preferred stock	8,870,626	13,547,780
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock	3,306
Additional paid in capital - preferred stock	$ 1,876,768

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	1,307,565,888	65,695,213
Common stock, shares outstanding	1,307,565,888	65,695,213
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2,552,642	3,778,622
Preferred stock, shares outstanding	2,552,642	3,778,622
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	0
Preferred stock, shares issued	3,305,755	0
Preferred stock, shares outstanding	3,305,755	0

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Consulting revenues, net		$ 4,054
OPERATING EXPENSES
Sales and marketing expenses	11,500	111,662
Depreciation and amortization expenses		1,473
Professional fees	682,217	709,843
Reserved stock units granted	113,189	575,011
Stock based compensation	1,164,885	103,865
Payroll expenses	315,000	806,620
Research and development	104,208	203,037
General and administrative expenses	98,638	109,457
Total Operating Expenses	2,489,637	2,620,968
OPERATING LOSS	(2,489,637)	(2,616,914)
NON-OPERATING INCOME (EXPENSE)
Interest expense	(5,649,546)	(3,903,015)
Gain (loss) on settlement of debt	605,601	(310,086)
Grant income	17,583
Gain (loss) on fair value of derivative liability	(186,846)	408,488
Gain on sale of assets		2,800
Total Non-Operating Income (Expenses)	(5,213,208)	(3,801,813)
NET LOSS BEFORE PROVISION FOR INCOME TAXES	(7,702,845)	(6,418,727)
Provision for income taxes
NET LOSS	$ (7,702,845)	$ (6,418,727)
Net loss per share - basic and diluted	$ (0.02)	$ (0.13)
Weighted average common shares outstanding - basic	444,009,985	48,386,991

Statement of Changes in Stockho

Statement of Changes in Stockholders' Deficit - USD ($)	Series A Preferred [Member]	Additional Paid in Capital - Series A Preferred [Member]	Series B Preferred [Member]	Additional Paid in Capital - Series B Preferred [Member]	Common Stock [Member]	Additional Paid in Capital - Common [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2016	$ 3,774	$ 14,140,797			$ 31,744	$ 40,672,825	$ (57,869,440)	$ (3,020,300)
Balance, shares at Dec. 31, 2016	3,773,592				31,743,797
Stock issued for: Settlement of debt					$ 3,040	217,803		220,843
Stock issued for: Settlement of debt, shares					3,040,239
Stock issued for: Accounts payable and accrued liabilities	$ 343	1,011,454			$ 3,096	306,354		1,321,247
Stock issued for: Accounts payable and accrued liabilities, shares	343,279				3,096,483
Stock issued for: Services					$ 2,302	252,136		254,438
Stock issued for: Services. shares					2,302,194
Stock issued for: Loan fees	$ 1,471	2,699,682						2,701,153
Stock issued for: Loan fees, shares	1,471,001
Conversion of preferred stock into common stock	$ (1,809)	(4,304,153)			$ 18,693	4,287,269
Conversion of preferred stock into common stock, shares	(1,809,250)				18,692,500
Restricted units vested					$ 6,820	(6,820)
Restricted units vested, shares					6,820,000
Reserved shares for services						575,011		575,011
Options and warrants issued for services						103,865		103,865
Net loss for the year							(6,418,727)	(6,418,727)
Balance at Dec. 31, 2017	$ 3,779	13,547,780			$ 65,695	46,408,443	(64,288,167)	(4,262,470)
Balance, shares at Dec. 31, 2017	3,778,622				65,695,213
Stock issued for: Settlement of debt			$ 2,996	1,542,078	$ 1,028,230	4,607,678		7,180,982
Stock issued for: Settlement of debt, shares			2,995,755		1,028,230,303
Stock issued for: Accounts payable and accrued liabilities			$ 200	279,800	$ 62,263	1,323,033		1,665,296
Stock issued for: Accounts payable and accrued liabilities, shares			200,000		62,262,562
Stock issued for: Services					$ 10	439		449
Stock issued for: Services. shares					10,000
Conversion of preferred stock into common stock	$ (1,226)	(4,677,154)			$ 12,260	4,666,120
Conversion of preferred stock into common stock, shares	(1,225,981)				12,259,810
Restricted units vested					$ 2,480	(2,480)
Restricted units vested, shares					2,480,000
Reserved shares for services						113,189		113,189
Stock issued for: Cash			$ 110	54,890	$ 136,628	546,512		738,140
Stock issued for: Cash, shares			110,000		136,628,000
Options and warrants issued for services						1,325,085		1,325,085
Net loss for the year							(7,702,845)	(7,702,845)
Balance at Dec. 31, 2018	$ 2,553	$ 8,870,626	$ 3,306	$ 1,876,768	$ 1,307,566	$ 58,988,019	$ (71,991,012)	$ (942,174)
Balance, shares at Dec. 31, 2018	2,552,641		3,305,755		1,307,565,888

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOW FROM OPERTING ACTIVIITES
Net loss	$ (7,702,845)	$ (6,418,727)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		1,473
Amortization of convertible debt discount	791,928	2,023,144
(Gain) loss on fair value of derivative liability	186,846	(408,488)
(Gain) loss on settlement of debt	(605,601)	310,086
New derivatives recorded as loan fees	4,636,517
(Gain) on sale of assets		(2,800)
Preferred stock issued for services		365,988
Preferred and common stock issued for loan fees		1,488,650
Common stock issued for services	449	254,438
Stock options and warrants for services	1,325,085	103,865
Reserved stock units issued for services	113,189	575,011
Changes in assets and liabilities
Prepaid expenses and other assets	(3,612)	5,254
Accounts payable and accrued expenses	(1,338)	102,316
Accounts payable and accrued expenses from related party	(128,178)	(52,421)
Payroll liabilities	466,941	(25,965)
Accrued interest	220,165	390,101
Total adjustments	7,002,391	5,130,652
Net cash used in operating activities	(700,454)	(1,288,075)
CASH FLOWS FROM INVESTING ACTIVITIES
Sale of equipment		2,800
Net cash provided by investing activities		2,800
CASH FLOWS FROM FINANCING ACTIVITES
Proceeds from convertible notes	50,000	1,230,334
Payments of convertible notes	(200,000)
Payments made for loan fees		(101,631)
Proceeds from sale of preferred stock	55,000
Proceeds from sale of common stock	683,140
Proceeds from related party and shareholder advances	109,491	137,000
Net cash provided by financing activities	697,631	1,265,703
NET DECREASE IN CASH	(2,823)	(19,572)
CASH - BEGINNING OF YEAR	8,317	27,889
CASH - END OF YEAR	5,494	8,317
CASH PAID DURING THE YEAR FOR:
Interest expense
Income taxes
SUPPLEMENTAL INFORMATION - NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of notes payable for common stock	7,290,473	358,860
Conversion of accounts payable and accrued payroll for common and preferred stock	1,665,296	660,727
Conversion of preferred stock into common stock	4,678,380	4,305,962
Preferred shares issued for discount of debt		1,212,503
Vesting of restricted stock units	2,480	6,820
Reclassification of shareholder advances to convertible notes payable	35,212	137,000
Recognition of debt discount for derivative liability		99,660
Reclassification of accrued interest to related party notes payable and convertible notes payable	$ 1,343	$ 121,308

Organization & Basis of Present

Organization & Basis of Presentation	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization & Basis of Presentation	NOTE 1: ORGANIZATION & BASIS OF PRESENTATION Business Overview Vivos Inc. (the “ Company SMSC Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.” The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device RadioGel™ for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer. The Company’s current focus is on the development of its RadioGel™ device. RadioGel™ is an injectable particle-gel, for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel™ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, one micron, yttrium-90 phosphate particles (“ Y-90 The Company’s lead brachytherapy products, including RadioGel™, incorporate patented technology developed for Battelle Memorial Institute (“ Battelle Battelle License The Company is currently focusing on obtaining approval from the Food and Drug Administration ( “FDA” In February 2014, the FDA ruled the device as not substantially equivalent due to a lack of a predicate device and it was therefore classified as a Class III device. Class III devices are generally the highest risk devices and are therefore subject to the highest level of regulatory review, control and oversight. Class III devices must typically be approved by the FDA before they are marketed. Class II devices represent lower risk devices than Class III and require fewer regulatory controls to provide reasonable assurance of the device’s safety and effectiveness. In contrast, Class I devices are deemed to be lower risk than Class II or III, and are therefore subject to the least regulatory controls. The Company is currently developing test plans to address issues raised by the FDA in connection with the Company’s previous submissions regarding RadioGel™, including developing specific test plans and specific indication of use. The Company intends to request that the FDA grant approval to re-apply for de novo See also Annual Report IsoPet Solutions The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet ® ® ® Dog A was treated for canine soft tissue sarcoma in June 2018. Response evaluation criteria in solid tumors (“ RECIST Dog C was treated in January 2019. This very large, half-pound, tumor was initially scheduled for therapy in December 2018 but had to be rescheduled due to the hydrogel not meeting our rigid specifications. From this, we learned that frozen hydrogel has a limited shelf life and this allowed us to make the appropriate adjustments to our product specifications. This patient had mild to moderate acute radiation side effects and has SD (stable disease) one-month post treatment. The February follow-up included a CT scan. The mass showed no new growth and measured almost the same as it did at the time of treatment. There is a small region at the bottom of the tumor where the mass seems to be draining. The tumor around the highest dose region appears dead with no blood supply, according to the CT. Dog C was outside of the scope of our criteria as an eligible patient prospect and we deem the patient as likely terminal, however, we treated it for humanitarian reasons and for discovery to determine residual effects of the treatment. Dog D was treated for canine soft tissue sarcoma in February 2019, and we are awaiting a follow-up appointment for an examination of the dog. These animal therapies generate data to assure the private veterinary clinics of the safety and efficacy of IsoPet ® The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet ® Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $2.3 million annually to maintain current operating activities. Over the next 12 to 24 months, the Company believes it will cost approximately $5.0 million to $10.0 million to: (1) fund the FDA approval process and initial deployment of the brachytherapy products, and (2) initiate regulatory approval processes outside of the United States. The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or additional capital raises. Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy. In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel™ and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations. As of December 31, 2018, the Company has $5,494 cash on hand. There are currently commitments to vendors for products and services purchased that will necessitate liquidation of the Company if it is unable to raise additional capital. The current level of cash is not enough to cover the fixed and variable obligations of the Company. The Company was able to execute the following transactions to improve their balance sheet and decrease the liabilities incurred and increase their cash flow: ● On October 10, 2018, the Company successfully completed the terms of certain Path Forward and Standstill Agreements previously entered into by and between the Company and certain debtholders (the “ Path Forward Agreements ● On October 10, 2018 the Company consummated a private placement transaction, resulting in net proceeds to the Company of $738,140. In addition, the Company issued an aggregate of 287,168,409 shares of its common stock, 695,302 shares of Series B Convertible Preferred, and warrants to purchase that number of shares of common stock equal to 50% of the shares of common stock issued in the private placement valued at $3,352,068 from the exchange of notes, past due executive compensation, and certain other liabilities. All shares issued in the private placement are restricted securities. The warrants have a two-year term and are exercisable at a price of $0.01 per share. Assuming the Company is successful in the Company’s sales/development effort, it believes that it will be able to raise additional funds through strategic agreements or the sale of the Company’s stock to either current or new stockholders. There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price. The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates. Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these audited financial statements so as to conform to current period classifications. Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Inventory Inventory is reported at the lower of cost or market, determined using the first-in, first-out basis, or net realizable value. All inventories consisted of finished goods. The Company has no inventory for the years ended December 31, 2018 and 2017. Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2018 and 2017, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ ASC Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments at fair value on a recurring basis. There were no assets and liabilities measured at fair value on a recurring basis at December 31, 2018 and 2017, respectively however during the years ended December 31, 2018 and 2017 there were Level 3 derivative liabilities measured at fair value. Derivative Liabilities The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ ASC 815 The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings. The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using the Black-Scholes model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock. Fixed Assets Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset. Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down. License Fees License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. Effective March 2012, the Company entered into an exclusive license agreement with Battelle Memorial Institute regarding the use of its patented RadioGel™ technology. This license agreement originally called for a $17,500 nonrefundable license fee and a royalty based on a percent of gross sales for licensed products sold; the license agreement also contains a minimum royalty amount to be paid each year starting with 2013. The license agreement was most recently amended on December 20, 2018, and pursuant to the amendment the maintenance fee schedule was updated for minimum royalties, as well as the increase in royalties from one percent (1%) to two percent (2%). Future minimum royalties for the years ended December 31 are noted below: Calendar Year Minimum Royalties per Calendar Year 2019 $ 10,000 2020 10,000 2021 25,000 2022 25,000 Total $ 70.000 The Company periodically reviews the carrying values of capitalized license fees and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. The Company entered into a Letter Amendment #2 with Battelle Memorial Institute on December 20, 2018. as a result of this Amendment, the Company has agreed to revised terms regarding the license fee as indicated in the chart above. $10,000 of this fee due within 1 year relates to the 2018 license fee which was paid in January 2019. The Company also agreed to increase the royalty fee on net sales from 1% to 2%. Amortization is computed using the straight-line method over the estimated useful live of three years. Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues. The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such costs in the years ended December 31, 2018 and 2017, respectively. Revenue Recognition In May 2014, the Financial Accounting Standards Board (“F ASB ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows. Revenue for the year ended December 31, 2017 consisted of consulting revenue. The Company recognized revenue as consulting services had been performed. Prepayments, if any, received from customers prior to the services being performed were recorded as deferred revenue. In these cases, when the services were performed, the amount recorded as deferred revenue was recognized as revenue. The Company did not accrue for sales returns and other allowances as it had not experienced any returns or other allowances. Income from Grants and Deferred Income Government grants are recognized when all conditions of such grants are fulfilled or there is reasonable assurance that they will be fulfilled. The Company has chosen to recognize income from grants as it incurs costs associated with those grants, and until such time as it recognizes the grant as income those funds received will be classified as deferred income on the balance sheet. On December 22, 2017, the Company received notification that Washington State University awarded it $17,500 of grant funds from the sub-award project entitled “ Optimized Injectable Radiogels for High-dose Therapy of Non-Resectable Solid Tumors Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the years ended December 31, 2018 and 2017, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of December 31, 2018 and 2017, which include the following: December 31, 2018 December 31, 2017 Convertible debt 17,594 18,155,788 Preferred stock 356,101,920 37,786,220 Common stock options 90,544,169 1,097,623 Common stock warrants 184,419,772 304,201 Total potential dilutive securities 631,083,455 57,343,832 Research and Development Costs Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $104,208 and $203,037 research and development costs for the years ended December 31, 2018, and 2017, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the years then ended. Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. There were no tradeshow expenses incurred and not expensed for the years ended December 31, 2018, and 2017, respectively. During the years ended December 31, 2018 and 2017, the Company incurred $11,500 and $111,662, respectively, in advertising and marketing costs. Shipping and Handling Costs Shipping and handling costs are expensed as incurred and included in cost of materials. Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. See Note 10 - Subsequent Events for description of lawsuit filed against the Company on January 28, 2019. In addition, the Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2018 and 2017. Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the years ended December 31, 2018 and 2017. The Company did not have any deferred tax liability or asset on its balance sheet on December 31, 2018 and 2017. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2018 and 2017, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months. The Tax Cuts and Jobs Act (the “ Act Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC Topic 718, Compensation – Stock Compensation. Under FASB ASC Topic. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation.” The update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. An entity shall account for the effects of a modification described in ASC paragraphs 718-20-35-3 through 35-9, unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The provisions of this update become effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The Company’s adoption of this guidance on January 1, 2018 did not have a material impact on the Company’s results of operations, financial position and related disclosures. In June 2018, the FASB issued ASU No. 2018-07 “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The guidance is effective for public companies for fiscal years, and interim fiscal periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The adoption of this standard did not have a material impact on its financial statements. Recent Accounting Pronouncements In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash,” or ASU 2016-18. ASU 2016-18 is intended to clarify how entities present restricted cash in the statement of cash flows. The guidance requires entities to show the changes in the total of cash and cash equivalents and restricted cash in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash in the statement of cash flows. When cash and cash equivalents and restricted cash are presented in more than one line-item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and is to be applied retrospectively. Early adoption was permitted, including adoption in an interim period. The adoption did not have a material impact on the Company’s financial statements. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates Step 2 from the goodwill impairment test. When an indication of impairment was identified after performing the first step of the goodwill impairment test, Step 2 required that an entity determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) using the same procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Under the amendments in ASU No. 2017-04, an entity would perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. An entity would recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value. In addition, an entity must consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. A public business entity that is a SEC filer should adopt the amendments in ASU No. 2017-04 for its annual, or any interim, good will impairment tests in fiscal years beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. In July 2017, the FASB issued ASU 2017-11 “Earnings Per Share (Topic 260).” The amendments in the update change the classification of certain equity-linked financial instruments (or embedded features) with down round features. The amendments also clarify existing disclosure requirements for equity-classified instruments. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (“EPS”) in accordance with Topic 260, Earnings Per Share, to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features would be subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). For public business entities, the amendments in Part I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption did not have a material impact on the Company’s financial statements. In August 2017, the FASB issued ASU 2017-12 “Derivatives and Hedging (Topic 815) Targeted Improvements to Accounting for Hedging Activities.” ASU 2017-12 eliminates the requirement to separately measure and report hedge ineffectiveness and generally requires the entire change in the fair value of a hedging instrument to be presented in the same income statement line as the hedged item. The guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The guidance is effective for the Company beginning after December 15, 2018, although early adoption is permitted. The Company as of December 31, 2018 does not have any derivative liabilities and as a result does not believe the guidance will have a material impact on its financial statements. In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements,” which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Fixed Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Fixed Assets	NOTE 3: FIXED ASSETS Fixed assets consist of the following at December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Production equipment $ 15,182 $ 15,182 Less accumulated depreciation (15,182 ) (15,182 ) $ - $ - Depreciation expense for the above fixed assets for the years ended December 31, 2018 and 2017 was $0 and $1,473, respectively. During the year ended December 31, 2017, the Company abandoned production equipment, building, leasehold improvements, and office equipment with an original cost totaling $14,594.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 4: RELATED PARTY TRANSACTIONS Related Party Convertible Notes Payable As of December 31, 2018 and 2017, the Company had the following related party convertible notes outstanding: December 31, 2018 December 31, 2017 Principal (net) Accrued Interest Principal (net) Accrued Interest March 2017 $332,195 Note, 10% interest, due May 2017 $ - $ - $ 383,771 $ 29,230 Total Convertible Notes Payable, Net $ - $ - $ 383,771 $ 29,230 In March 2017, the Company combined Outstanding Notes owed to a director and major stockholder, along with $51,576 of accrued interest payable, into one promissory note (the “ Related Party Note Qualified Financing The Company has outstanding accrued interest in the amount of $1,054 from old related party notes that the principal had been paid off in full. Interest expense for the years ended December 31, 2018 and 2017 on the related party convertible notes payable amounted to $29,650 and $29,230, respectively. Related Party Payables The Company periodically receives advances for operating funds from related parties or has related parties make payments on the Company’s behalf. As a result of these activities the Company had related party payables of $38,610 and $57,297 as of December 31, 2018 and 2017, respectively. All related party advances that occurred through September 30, 2018 were converted into shares of common stock, and Series B Convertible Preferred stock and warrants on October 30, 2018. Preferred and Common Shares Issued to Officers and Directors During 2018, the Company issued 38,662,562 shares of common stock and warrants to purchase shares of common stock totaling 19,331,281 in settlement of accrued compensation valued at $541,276. The warrants were valued at $238,973 and the Company reflected $586,936 as a loss on conversion of debt. During 2018, the Company issued 3,600,000 shares of common stock in settlement of accounts payable and notes payable valued at $50,400. The Company granted 1,800,000 warrants in connection with this transaction and recognized a loss of $35,400 in accordance with this settlement. During 2017, the Company issued 100,000 shares of its Series A Convertible Preferred to its CEO, in settlement for $32,308 of accrued payroll, $67,692 of accounts payable, and wages valued at $199,690. During 2017, the Company issued 83,279 shares of its Series A Convertible Preferred to its former CFO, in settlement for $83,280 of accrued payroll and wages valued at $166,299. Rent Expenses The Company was renting office space from a significant shareholder and director of the Company on a month-to-month basis with a monthly payment of $1,500. This rental agreement was terminated as of April 1, 2017. Rental expense for the years ended December 31, 2018 and 2017 for the corporate offices was $0 and $4,500, respectively.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 5: CONVERTIBLE NOTES PAYABLE As of December 31, 2018 and 2017, the Company had the following convertible notes outstanding: December 31, 2018 December 31, 2017 Principal (net) Accrued Interest Principal (net) Accrued Interest July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014 $ 45,000 $ 34,603 $ 45,000 29,218 May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015 - 17,341 - 17,341 October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $560,913, respectively - 5,953 - 5,953 January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016 - 696 - 696 May 2017 $2,378,155 Notes convertible into common stock after April 15, 2018 at a $0.20 conversion price (subject to adjustment), 7.5% interest, due May 2018, net of debt discounts of $0 and $544,845, respectively - - 1,833,310 178,304 May 2017 $820,420 Notes convertible into common stock after April 15, 2018 at a $0.12 conversion price (subject to adjustment), 7.5% interest, due May 2018, net of debt discounts of $0 and $147,335, respectively - - 500,703 52,831 May 2017 $110,312 Notes convertible after April 15, 2018 into common stock at a $0.13 conversion price (subject to adjustment), 7.5% interest, due May 2018, net of debt discounts of $0 and $25,085, respectively - - 85,227 15,773 November 2017 $166,666 Note convertible at maturity or upon the issuance of a variable security at a $0.12 conversion price (subject to adjustment), with a one-time interest charge of 10%, due April 15, 2018, net of debt discounts of $0 and $74,662, respectively - - 92,004 16,667 Penalties on notes in default 8,824 - 7,028 - Total Convertible Notes Payable, Net $ 53,824 $ 58,593 $ 2,563,272 $ 316,784 Interest expense for the years ended December 31, 2018 and 2017 on the convertible notes payable amounted to $187,741 and $268,961, respectively. During the year ending December 31, 2017, the Company received proceeds from the issuance of 10% Convertible Notes (“ Convertible Notes Debentures The Company recorded $322,381 of conversions on certain outstanding notes. The Company also recorded amortization of $2,023,144 on outstanding note debt discounts. Lastly, the Company paid $101,631 in cash for loan fees and issued 843,699 shares of the Company’s Series A Convertible Preferred Stock (“ Series A Convertible Preferred The May 2017 notes totaling $3,136,506, $2,419,240 after debt discounts, had a December 2017 due date which was extended to May 2018. The November 2017 Note totaling $166,666, $92,004 after debt discount, included an Investor’s Put Option whereby if the Company’s stock was not listed on the Nasdaq or NYSE by January 31, 2018, the lender had the right to require the Company to repurchase the Note at any time after January 31, 2018 in an amount equal to 130% of the sum of the Principal plus all accrued and unpaid interest. The Investor issued notice February 2, 2018 exercising it’s Put Option and requiring the Company repurchase the Note on April 19, 2018 in the aggregate amount of $228,332. The investor may elect to cancel the repurchase notice at any time prior to receiving the repurchase payment. On October 10, 2018, the Company successfully completed the terms of the Path Forward Agreements The Company entered into a convertible note in the amount of $50,000 in July 2018 with an interest rate of 8%. This note was convertible upon a Company capital raise of at least $500,000. On October 30, 2018, the Company converted this note into 12,000,000 shares of common stock at a conversion rate of $0.014 (total of $60,000 which includes $10,000 of interest and other costs) and recognized a loss on extinguishment of $108,916 on this conversion. See Note 6 for discussion on the derivative liabilities associated with the various convertible notes.

Derivative Liability

Derivative Liability	12 Months Ended
	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	NOTE 6: DERIVATIVE LIABILITY During the years ended December 31, 2018 and 2017, certain convertible notes become convertible on a set date at variable conversion rates. Upon becoming convertible, the Company bifurcated the embedded conversion feature and recorded a derivative liability at fair value with the offsetting entry recorded in the statement of operations. The activity in the derivative liability account during the years ended December 31, 2018 and 2017 is summarized as follows: Warrants Conversion Feature Total Derivative Liability at December 31, 2016 58 324,474 324,532 Derivative Liability Recorded on New Instruments - 99,661 99,661 Elimination of Liability on Conversion - - - (Gain) on Settlement of Debt - (15,704 ) (15,704 ) Change in Fair Value (58 ) (408,431 ) (408,489 ) Derivative Liability at December 31, 2017 - - - Derivative Liability Recorded on New Instruments - 4,636,517 4,636,517 Elimination of Liability on Conversion - (4,217,762 ) (4,217,762 ) (Gain) on Settlement of Debt - (605,601 ) (605,601 ) Change in Fair Value - 186,846 186,846 Derivative Liability at December 31, 2018 - - - The Company uses the Black-Scholes pricing model to estimate fair value for those instruments convertible into common stock at inception, at conversion date, and at each reporting date. During the years ending December 31, 2018 and 2017, the Company used the following assumptions in their Black-Scholes model: December 31, 2018 December 31, 2017 Warrants Conversion Feature Warrants Conversion Feature Risk-free interest rate n/a 1.62%-2.59 % 1.39 n/a Expected life in years n/a 0.11-1.10 0.25 n/a Dividend yield n/a 0 % 0 % n/a Expected volatility n/a 174.46%-519.42 % 187.59 % n/a

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 7: INCOME TAXES The Tax Cuts and Jobs Act (the “ Act Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Net deferred tax assets consist of the following components as of December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Deferred tax assets: Net operating loss carryover $ 5,760,000 $ 5,640,000 Depreciation - - Related party accrual 2,300 110,600 Capital Loss Carryover 3,400 3,400 Deferred tax liabilities Depreciation (2,100 ) (2,100 ) Valuation allowance (5,763,600 ) (5,751,900 ) Net deferred tax asset $ - $ - The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2018 and 2017 due to the following: December 31, 2018 December 31, 2017 Book income (loss) $ (1,617,600 ) $ (1,347,900 ) Grant income - - ) Depreciation (1,100 ) (700 ) Intangible asset impairment - - Related party accrual (108,300 ) (100 ) Meals and entertainment 300 200 Stock for services 100 130,300 Options expense 302,000 142,600 Non-cash interest expense 1,046,900 946,500 Other non-deductible expenses 261,800 (12,200 ) Valuation allowance 115,900 141,300 Income tax expense $ - $ - At December 31, 2018, the Company had net operating loss carryforwards of approximately $27,408,300 that may be offset against future taxable income from the year 2018 through 2037. Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryforwards for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carryforwards may be limited as to use in future years. Topic 740 provides guidance on the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. At the adoption date of January 1, 2007, the Company had no unrecognized tax benefit, which would affect the effective tax rate if recognized. The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operations in the provision for income taxes. As of December 31, 2018, the Company had no accrued interest or penalties related to uncertain tax positions. The Company files income tax returns in the U.S. federal jurisdiction. The Company is located in the state of Washington and Washington state does not require the filing of income taxes. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2015.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Stockholders' Deficit	NOTE 8: STOCKHOLDERS’ DEFICIT Common Stock The Company has 2,000,000,000 shares of common stock authorized, with a par value of $0.001, and as of December 31, 2018 and 2017, the Company has 1,307,565,888 and 65,695,213 shares issued and outstanding, respectively. Preferred Stock As of December 31, 2018 and 2017, the Company has 20,000,000 shares of Preferred stock authorized with a par value of $0.001. The Company’s Board of Directors is authorized to provide for the issuance of shares of preferred stock in one or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series without further vote or action by the shareholders. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others. The following is a summary of the rights and preferences of the Series A Convertible Preferred, which summary is not meant to be a complete description of those terms. On October 8, 2018 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series B Convertible Preferred Stock,” consisting of Five Million (5,000,000) shares. Series A Convertible Preferred Stock In June 2015, the Series A Certificate of Designation was filed with the Delaware Secretary of State to designate 2.5 million shares of our preferred stock as Series A Convertible Preferred. Effective March 31, 2016, the Company amended the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred of the Registrant, increasing the maximum number of shares of Series A Convertible Preferred from 2,500,000 shares to 5,000,000 shares. The following summarizes the current rights and preferences of the Series A Convertible Preferred: Liquidation Preference Dividends Conversion Series A Conversion Shares In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $5.0 million, all issued and outstanding shares of Series A Convertible Preferred at that time will automatically convert into Series A Conversion Shares. Redemption Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Series B Convertible Preferred Stock In October 2018, the Series B Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series B Convertible Preferred. The following summarizes the current rights and preferences of the Series B Convertible Preferred: Liquidation Preference Dividends Conversion Series B Conversion Shares Redemption Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Common Stock Issuances Common Stock Issued for Services During 2018, the Company issued 10,000 shares of common stock for services valued at $449. During 2017, the Company issued 2,302,194 shares of common stock for services valued at $254,438. Common Stock Issued for the Exercise of Options and Warrants During 2018, the Company did not issue any shares of common stock for the exercise of options and warrants. During 2017, the Company did not issue any shares of common stock for the exercise of options and warrants. Common Stock and Preferred Stock Issued for Settlement and Conversion of Debt During 2018, the Company issued 1,028,230,303 shares of common stock and 2,995,755 shares of Series B Convertible Preferred in conjunction with the settlement of $3,545,378 worth of convertible debt (both related and non-related) and $506,245 worth of accrued interest (both related and non-related). As part of these conversions, the Company recognized offsets of $4,823,363 for derivative liabilities and recognized a gain on extinguishment of debt of $1,694,005. During 2017, the Company issued 3,040,239 shares of common stock in conjunction with the settlement of $322,381 worth of convertible debt and $36,479 worth of accrued interest. The shares were valued at $334,048 and $159,299 worth of debt discount was written off, with $21,282 recognized as a loss on the settlement of debt and $113,205 recorded to Additional Paid in Capital upon conversion. Common Stock Issued for Conversion of Preferred Stock During 2018, the Company issued 12,259,810 shares of common stock valued at $4,678,380 in exchange for 1,225,981 shares of Series A Convertible Preferred. During 2017, the Company issued 18,692,500 shares of common stock valued at $4,305,962 in exchange for 1,809,250 shares of Series A Convertible Preferred. Common Stock Issued for Cash During 2018, the Company issued 136,628,000 shares of common stock for cash in the amount of $683,140. Preferred Stock Issuances Preferred Stock Issued for Cash During 2018, the Company issued no shares of Series A Convertible Preferred for cash. During 2018, the Company issued 110,000 shares of Series B Convertible Preferred for cash in the amount of $55,000. During 2017, the Company issued no shares of Series A Convertible Preferred for cash. Preferred Stock Issued for Exercise of Warrants During 2018, the Company issued no shares of Series A Convertible Preferred for the exercise of warrants. During 2018, the Company issued no shares of Series B Convertible Preferred for the exercise of warrants. During 2017, the Company issued no shares of Series A Convertible Preferred for the exercise of warrants. Preferred Stock Issued for Warrants Surrendered During 2018, the Company issued no shares of Series A Convertible Preferred for the surrender of warrants. During 2018, the Company issued no shares of Series B Convertible Preferred for the surrender of warrants. During 2017, the Company issued no shares of Series A Convertible Preferred for the surrender of warrants. Preferred Stock Issued for Services During 2018, the Company issued no shares of its Series A Convertible Preferred for services. During 2018, the Company issued no shares of its Series B Convertible Preferred for services. During 2017, the Company issued no shares of its Series A Convertible Preferred for services. Preferred Stock Issued for Loan Fees During 2018, the Company issued no shares of Series A Convertible Preferred for loan fees. During 2018, the Company issued no shares of Series B Convertible Preferred for loan fees. During 2017, the Company issued 843,699 shares of Series A Convertible Preferred, valued at $1,212,503, for loan fees, and recorded $1,212,503 as debt discount. During 2017, the Company issued 627,302 shares of Series A Convertible Preferred, valued at $1,488,650, to current note holders for the due date extension on the conversion date of the related notes from December 15, 2017 to May 9, 2018. Preferred Stock Issued for Debt Extinguishment For 2018 activity, see above for the Preferred Series A Convertible Preferred and Series B Convertible Preferred that were issued along with the common stock to convert debt and accrued interest. During 2017, the Company issued no shares of Series A Convertible Preferred in exchange for debt extinguishment. Common and Preferred Stock Issued for Accounts Payable and Accrued Liabilities During 2018, no shares of Series A Convertible Preferred were issued for accounts payable and accrued liabilities. During 2018, 62,262,562 shares of common stock and 200,000 shares of Series B Convertible Preferred were issued to officers and consultants for accrued compensation as well as to settle accounts payable and shareholder advances made during the year. The value of these shares were $1,665,285. The Company recognized a loss on extinguishment on these issuances of $1,256,972. During 2017, the Company issued 183,279 shares of Series A Convertible Preferred to the CEO and CFO, in exchange for $115,587 of accrued payroll, $67,692 of accounts payable and wages valued at $365,989. Additionally, the Company issued 3,096,483 shares of Common Stock and 160,000 shares of Series A Convertible Preferred to third parties and former employees to extinguish $205,283 worth of accounts payable and $272,164 of accrued payroll, which resulted in the Company recording a loss on extinguishment of debt of $294,530. The Company recorded a gain on debt extinguishment of $35,217 as a result of offsetting certain payables that were written off after statutes of limitations had passed on payment. Common Stock Options The following schedule summarizes the changes in the Company’s stock options: Weighted Weighted Options Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2016 2,402,500 $ 0.50-15.00 3.91 years $ - $ 0.81 Options granted - $ - - $ - Options exercised - $ - - $ - Options expired (1,180,000 ) $ 0.12-.0.15 - $ - Balance at December 31, 2017 1,222,500 $ 0.50-15.00 2.91 years $ - $ 1.08 Options granted 89,321,669 $ 0.014 - $ - Options exercised - $ - - $ - Options expired - $ - - $ - Balance at December 31, 2018 90,544,169 $ 0.014-15.00 6.75 years $ - $ 0.03 Exercisable at December 31, 2018 90,544,669 $ 0.014-15.00 6.75 years $ - $ 0.03 During the years ending December 31, 2018 and 2017, the Company recognized $1,164,885 and $103,865, respectively, worth of stock based compensation related to the vesting of it stock options. Common Stock Warrants The following schedule summarizes the changes in the Company’s common stock warrants: Weighted Weighted Warrants Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2016 3,579,505 $ 0.1-10.00 1.90 years $ 2,052,699 $ 4.45 Warrants granted - $ - - $ Warrants exercised - $ - - $ Warrants expired/cancelled (3,275,305 ) $ 4.62 - $ Balance at December 31, 2017 304,200 $ 1.19 1.19 years $ 749 $ 2.63 Warrants granted 184,349,305 $ 0.01 - $ Warrants exercised - $ - - $ Warrants expired/cancelled (233,733 ) $ 0.40 - $ Balance at December 31, 2018 184,419,772 $ 0.01 1.77 years $ - $ 0.01 Exercisable at December 31, 2018 184,419,772 $ 0.01 1.77 years $ - $ 0.01 For the year ended December 31, 2018, the Company granted 19,331,281 warrants to settle accrued payroll, 63,404,024 warrants to settle other payables, 21,800,000 warrants to settle accounts payable, 6,000,000 warrants issued for consulting services and 73,814,000 warrants in the issuance of shares issued for cash. The Company did not grant any warrants in the year ended December 31, 2017. Restricted Stock Units The following schedule summarizes the changes in the Company’s restricted stock units: Weighted Number Average Of Grant Date Shares Fair Value Balance at December 31, 2016 - $ - RSU’s granted 12,560,000 $ 0.07 RSU’s vested (6,820,000 ) $ - RSU’s forfeited - $ - Balance at December 31, 2017 5,740,000 $ 0.07 RSU’s granted - $ 0.07 RSU’s vested (2,480,000 ) $ - RSU’s forfeited (1,160,000 ) $ - Balance at December 31, 2018 2,100,000 $ 0.07 During the years ended December 31, 2018 and 2017, the Company recognized $113,189 and $575,011 worth of expense related to the vesting of its RSU’s, respectively. As of December 31, 2018, the Company had $155,400 worth of expense yet to be recognized for RSU’s not yet vested.

Concentrations of Credit and Ot

Concentrations of Credit and Other Risks	12 Months Ended
	Dec. 31, 2018
Risks and Uncertainties [Abstract]
Concentrations of Credit and Other Risks	NOTE 9: CONCENTRATIONS OF CREDIT AND OTHER RISKS Accounts Receivable The Company had one customer that represented 100% of the Company’s total revenues for the year ended December 31, 2017. The customer that represented 100% of the Company’s total revenue for the year ended December 31, 2017 had no net accounts receivable balance at December 31, 2017. The loss of a significant customer representing the percentage of total revenue would have a temporary adverse effect on the Company’s revenue, which would continue until the Company located new customers to replace them. The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary. As of December 31, 2018 and 2017, the Company had no allowance or bad debt expense recorded. Product Purchases Some of the products the Company might market and components thereof are currently available only from a limited number of suppliers including the source for the main component in the Company’s products, Y-90 which is only derived from one source, several of which are international suppliers. Failure to obtain deliveries from these sources could have a material adverse effect on the Company’s ability to operate.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 10: SUBSEQUENT EVENTS Debt and Equity Transactions In January 2019, the Company received $100,000 in gross proceeds resulting from the issuance to accredited investors of 10,000,000 shares of common stock, 100,000 shares of Series B Convertible Preferred and warrants to purchase 10,000,000 shares of common stock. The Company issued a one-year 8% promissory note in January 2019 with a related party in the amount of $60,000. The Company issued two six-month 8% promissory notes in February 2019 totaling $100,000 which includes the issuance of warrants to purchase 10,000,000 shares of common stock with a term of two-years. The Company issued 52,421,800 shares of common stock in consideration for the conversion of 524,218 shares of Series B Convertible Preferred. The Company issued warrants to consultants in February 2019 to purchase 675,000 shares of common stock. Corporate Matters The Company’s board of directors approved a resolution to reverse split the Company’s shares of common stock on a 1 for 8 basis, and reduce the number of authorized shares of common stock from 2,000,000,000 to 950,000,000. The Company intends to seek stockholder approval of the reverse split in the near term. Legal Matters On January 28, 2019, James Katzaroff, (“ Plaintiff Release Complaint

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.
Financial Statement Reclassification	Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these audited financial statements so as to conform to current period classifications.
Cash Equivalents	Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.
Inventory	Inventory Inventory is reported at the lower of cost or market, determined using the first-in, first-out basis, or net realizable value. All inventories consisted of finished goods. The Company has no inventory for the years ended December 31, 2018 and 2017.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2018 and 2017, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ ASC Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments at fair value on a recurring basis. There were no assets and liabilities measured at fair value on a recurring basis at December 31, 2018 and 2017, respectively however during the years ended December 31, 2018 and 2017 there were Level 3 derivative liabilities measured at fair value.
Derivative Liabilities	Derivative Liabilities The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ ASC 815 The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings. The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using the Black-Scholes model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock.
Fixed Assets	Fixed Assets Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset. Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.
License Fees	License Fees License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. Effective March 2012, the Company entered into an exclusive license agreement with Battelle Memorial Institute regarding the use of its patented RadioGel™ technology. This license agreement originally called for a $17,500 nonrefundable license fee and a royalty based on a percent of gross sales for licensed products sold; the license agreement also contains a minimum royalty amount to be paid each year starting with 2013. The license agreement was most recently amended on December 20, 2018, and pursuant to the amendment the maintenance fee schedule was updated for minimum royalties, as well as the increase in royalties from one percent (1%) to two percent (2%). Future minimum royalties for the years ended December 31 are noted below: Calendar Year Minimum Royalties per Calendar Year 2019 $ 10,000 2020 10,000 2021 25,000 2022 25,000 Total $ 70.000 The Company periodically reviews the carrying values of capitalized license fees and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. The Company entered into a Letter Amendment #2 with Battelle Memorial Institute on December 20, 2018. as a result of this Amendment, the Company has agreed to revised terms regarding the license fee as indicated in the chart above. $10,000 of this fee due within 1 year relates to the 2018 license fee which was paid in January 2019. The Company also agreed to increase the royalty fee on net sales from 1% to 2%. Amortization is computed using the straight-line method over the estimated useful live of three years.
Patents and Intellectual Property	Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues. The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such costs in the years ended December 31, 2018 and 2017, respectively.
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (“F ASB ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows. Revenue for the year ended December 31, 2017 consisted of consulting revenue. The Company recognized revenue as consulting services had been performed. Prepayments, if any, received from customers prior to the services being performed were recorded as deferred revenue. In these cases, when the services were performed, the amount recorded as deferred revenue was recognized as revenue. The Company did not accrue for sales returns and other allowances as it had not experienced any returns or other allowances.
Income from Grants and Deferred Income	Income from Grants and Deferred Income Government grants are recognized when all conditions of such grants are fulfilled or there is reasonable assurance that they will be fulfilled. The Company has chosen to recognize income from grants as it incurs costs associated with those grants, and until such time as it recognizes the grant as income those funds received will be classified as deferred income on the balance sheet. On December 22, 2017, the Company received notification that Washington State University awarded it $17,500 of grant funds from the sub-award project entitled “ Optimized Injectable Radiogels for High-dose Therapy of Non-Resectable Solid Tumors
Loss Per Share	Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the years ended December 31, 2018 and 2017, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of December 31, 2018 and 2017, which include the following: December 31, 2018 December 31, 2017 Convertible debt 17,594 18,155,788 Preferred stock 356,101,920 37,786,220 Common stock options 90,544,169 1,097,623 Common stock warrants 184,419,772 304,201 Total potential dilutive securities 631,083,455 57,343,832
Research and Development Costs	Research and Development Costs Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $104,208 and $203,037 research and development costs for the years ended December 31, 2018, and 2017, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the years then ended.
Advertising and Marketing Costs	Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. There were no tradeshow expenses incurred and not expensed for the years ended December 31, 2018, and 2017, respectively. During the years ended December 31, 2018 and 2017, the Company incurred $11,500 and $111,662, respectively, in advertising and marketing costs.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs are expensed as incurred and included in cost of materials.
Contingencies	Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. See Note 10 - Subsequent Events for description of lawsuit filed against the Company on January 28, 2019. In addition, the Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2018 and 2017.
Income Taxes	Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the years ended December 31, 2018 and 2017. The Company did not have any deferred tax liability or asset on its balance sheet on December 31, 2018 and 2017. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2018 and 2017, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months. The Tax Cuts and Jobs Act (the “ Act
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC Topic 718, Compensation – Stock Compensation. Under FASB ASC Topic. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation”. The update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. An entity shall account for the effects of a modification described in ASC paragraphs 718-20-35-3 through 35-9, unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The provisions of this update become effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The Company’s adoption of this guidance on January 1, 2018 did not have a material impact on the Company’s results of operations, financial position and related disclosures. In June 2018, the FASB issued ASU No. 2018-07 “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The guidance is effective for public companies for fiscal years, and interim fiscal periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The adoption of this standard did not have a material impact on its financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash,” or ASU 2016-18. ASU 2016-18 is intended to clarify how entities present restricted cash in the statement of cash flows. The guidance requires entities to show the changes in the total of cash and cash equivalents and restricted cash in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash in the statement of cash flows. When cash and cash equivalents and restricted cash are presented in more than one line-item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and is to be applied retrospectively. Early adoption was permitted, including adoption in an interim period. The adoption did not have a material impact on the Company’s financial statements. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates Step 2 from the goodwill impairment test. When an indication of impairment was identified after performing the first step of the goodwill impairment test, Step 2 required that an entity determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) using the same procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Under the amendments in ASU No. 2017-04, an entity would perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. An entity would recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value. In addition, an entity must consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. A public business entity that is a SEC filer should adopt the amendments in ASU No. 2017-04 for its annual, or any interim, good will impairment tests in fiscal years beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. In July 2017, the FASB issued ASU 2017-11 “Earnings Per Share (Topic 260)”. The amendments in the update change the classification of certain equity-linked financial instruments (or embedded features) with down round features. The amendments also clarify existing disclosure requirements for equity-classified instruments. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (“EPS”) in accordance with Topic 260, Earnings Per Share, to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features would be subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). For public business entities, the amendments in Part I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption did not have a material impact on the Company’s financial statements. In August 2017, the FASB issued ASU 2017-12 “Derivatives and Hedging (Topic 815) Targeted Improvements to Accounting for Hedging Activities”. ASU 2017-12 eliminates the requirement to separately measure and report hedge ineffectiveness and generally requires the entire change in the fair value of a hedging instrument to be presented in the same income statement line as the hedged item. The guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The guidance is effective for the Company beginning after December 15, 2018, although early adoption is permitted. The Company as of December 31, 2018 does not have any derivative liabilities and as a result does not believe the guidance will have a material impact on its financial statements. In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Depreciation Estimated Useful Life	Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years
Schedule of Future Minimum Royalties	Future minimum royalties for the years ended December 31 are noted below: Calendar Year Minimum Royalties per Calendar Year 2019 $ 10,000 2020 10,000 2021 25,000 2022 25,000 Total $ 70.000
Schedule of Dilutive Earnings Per Share	The following represent common stock equivalents that could be dilutive in the future as of December 31, 2018 and 2017, which include the following: December 31, 2018 December 31, 2017 Convertible debt 17,594 18,155,788 Preferred stock 356,101,920 37,786,220 Common stock options 90,544,169 1,097,623 Common stock warrants 184,419,772 304,201 Total potential dilutive securities 631,083,455 57,343,832

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Production equipment $ 15,182 $ 15,182 Less accumulated depreciation (15,182 ) (15,182 ) $ - $ -

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Schedule of Related Party Transaction	As of December 31, 2018 and 2017, the Company had the following related party convertible notes outstanding: December 31, 2018 December 31, 2017 Principal (net) Accrued Interest Principal (net) Accrued Interest March 2017 $332,195 Note, 10% interest, due May 2017 $ - $ - $ 383,771 $ 29,230 Total Convertible Notes Payable, Net $ - $ - $ 383,771 $ 29,230

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	As of December 31, 2018 and 2017, the Company had the following convertible notes outstanding: December 31, 2018 December 31, 2017 Principal (net) Accrued Interest Principal (net) Accrued Interest July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014 $ 45,000 $ 34,603 $ 45,000 29,218 May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015 - 17,341 - 17,341 October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $560,913, respectively - 5,953 - 5,953 January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016 - 696 - 696 May 2017 $2,378,155 Notes convertible into common stock after April 15, 2018 at a $0.20 conversion price (subject to adjustment), 7.5% interest, due May 2018, net of debt discounts of $0 and $544,845, respectively - - 1,833,310 178,304 May 2017 $820,420 Notes convertible into common stock after April 15, 2018 at a $0.12 conversion price (subject to adjustment), 7.5% interest, due May 2018, net of debt discounts of $0 and $147,335, respectively - - 500,703 52,831 May 2017 $110,312 Notes convertible after April 15, 2018 into common stock at a $0.13 conversion price (subject to adjustment), 7.5% interest, due May 2018, net of debt discounts of $0 and $25,085, respectively - - 85,227 15,773 November 2017 $166,666 Note convertible at maturity or upon the issuance of a variable security at a $0.12 conversion price (subject to adjustment), with a one-time interest charge of 10%, due April 15, 2018, net of debt discounts of $0 and $74,662, respectively - - 92,004 16,667 Penalties on notes in default 8,824 - 7,028 - Total Convertible Notes Payable, Net $ 53,824 $ 58,593 $ 2,563,272 $ 316,784

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liability Account Activity	The activity in the derivative liability account during the years ended December 31, 2018 and 2017 is summarized as follows: Warrants Conversion Feature Total Derivative Liability at December 31, 2016 58 324,474 324,532 Derivative Liability Recorded on New Instruments - 99,661 99,661 Elimination of Liability on Conversion - - - (Gain) on Settlement of Debt - (15,704 ) (15,704 ) Change in Fair Value (58 ) (408,431 ) (408,489 ) Derivative Liability at December 31, 2017 - - - Derivative Liability Recorded on New Instruments - 4,636,517 4,636,517 Elimination of Liability on Conversion - (4,217,762 ) (4,217,762 ) (Gain) on Settlement of Debt - (605,601 ) (605,601 ) Change in Fair Value - 186,846 186,846 Derivative Liability at December 31, 2018 - - -
Schedule of Assumptions for Fair Value Determination	During the years ending December 31, 2018 and 2017, the Company used the following assumptions in their Black-Scholes model: December 31, 2018 December 31, 2017 Warrants Conversion Feature Warrants Conversion Feature Risk-free interest rate n/a 1.62%-2.59 % 1.39 n/a Expected life in years n/a 0.11-1.10 0.25 n/a Dividend yield n/a 0 % 0 % n/a Expected volatility n/a 174.46%-519.42 % 187.59 % n/a

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Net Deferred Tax Assets	Net deferred tax assets consist of the following components as of December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Deferred tax assets: Net operating loss carryover $ 5,760,000 $ 5,640,000 Depreciation - - Related party accrual 2,300 110,600 Capital Loss Carryover 3,400 3,400 Deferred tax liabilities Depreciation (2,100 ) (2,100 ) Valuation allowance (5,763,600 ) (5,751,900 ) Net deferred tax asset $ - $ -
Schedule of Federal Income Tax Rate	The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2018 and 2017 due to the following: December 31, 2018 December 31, 2017 Book income (loss) $ (1,617,600 ) $ (1,347,900 ) Grant income - - ) Depreciation (1,100 ) (700 ) Intangible asset impairment - - Related party accrual (108,300 ) (100 ) Meals and entertainment 300 200 Stock for services 100 130,300 Options expense 302,000 142,600 Non-cash interest expense 1,046,900 946,500 Other non-deductible expenses 261,800 (12,200 ) Valuation allowance 115,900 141,300 Income tax expense $ - $ -

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Schedule of Changes in Stock Option	The following schedule summarizes the changes in the Company’s stock options: Weighted Weighted Options Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2016 2,402,500 $ 0.50-15.00 3.91 years $ - $ 0.81 Options granted - $ - - $ - Options exercised - $ - - $ - Options expired (1,180,000 ) $ 0.12-.0.15 - $ - Balance at December 31, 2017 1,222,500 $ 0.50-15.00 2.91 years $ - $ 1.08 Options granted 89,321,669 $ 0.014 - $ - Options exercised - $ - - $ - Options expired - $ - - $ - Balance at December 31, 2018 90,544,169 $ 0.014-15.00 6.75 years $ - $ 0.03 Exercisable at December 31, 2018 90,544,669 $ 0.014-15.00 6.75 years $ - $ 0.03
Schedule of Changes in Stock Warrants	The following schedule summarizes the changes in the Company’s common stock warrants: Weighted Weighted Warrants Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2016 3,579,505 $ 0.1-10.00 1.90 years $ 2,052,699 $ 4.45 Warrants granted - $ - - $ Warrants exercised - $ - - $ Warrants expired/cancelled (3,275,305 ) $ 4.62 - $ Balance at December 31, 2017 304,200 $ 1.19 1.19 years $ 749 $ 2.63 Warrants granted 184,349,305 $ 0.01 - $ Warrants exercised - $ - - $ Warrants expired/cancelled (233,733 ) $ 0.40 - $ Balance at December 31, 2018 184,419,772 $ 0.01 1.77 years $ - $ 0.01 Exercisable at December 31, 2018 184,419,772 $ 0.01 1.77 years $ - $ 0.01
Schedule of Changes in Restricted Stock Units	The following schedule summarizes the changes in the Company’s restricted stock units: Weighted Number Average Of Grant Date Shares Fair Value Balance at December 31, 2016 - $ - RSU’s granted 12,560,000 $ 0.07 RSU’s vested (6,820,000 ) $ - RSU’s forfeited - $ - Balance at December 31, 2017 5,740,000 $ 0.07 RSU’s granted - $ 0.07 RSU’s vested (2,480,000 ) $ - RSU’s forfeited (1,160,000 ) $ - Balance at December 31, 2018 2,100,000 $ 0.07

Organization & Basis of Prese_2

Organization & Basis of Presentation (Details Narrative) - USD ($)	Dec. 31, 2018	Oct. 30, 2018	Oct. 10, 2018	Dec. 31, 2018	Dec. 31, 2017	Oct. 31, 2018	Oct. 08, 2018
Common stock, authorized	2,000,000,000			2,000,000,000	2,000,000,000
Common stock, par value	$ 0.001			$ 0.001	$ 0.001
Preferred stock, authorized	20,000,000			20,000,000	20,000,000
Preferred stock, par value	$ 0.001			$ 0.001	$ 0.001
Current operation activities				$ 2,300,000
Cash	$ 5,494			$ 5,494	$ 8,317
Conversion of debt into stock				637,613,204	347,400
Private Placement [Member]
Proceeds from private placement			$ 738,140
Warrant to purchase of common stock percentage			50.00%
Warrant term			2 years
Warrant exercise price per share			$ 0.01
Private Placement [Member] | Executive [Member]
Proceeds from private placement			$ 3,352,068
Path Forward Agreements [Member] | Convertible Secured Debenture and Convertible Promissory [Member]
Outstanding debt amount			$ 2,253,538
Conversion of debt, price per share			$ 0.004
Minimum [Member]
Current operation activities				$ 5,000,000
Maximum [Member]
Current operation activities				$ 10,000,000
Series B Convertible Preferred Stock [Member]
Preferred stock, authorized	5,000,000			5,000,000	0	5,000,000	5,000,000
Preferred stock, par value							$ 0.001
Conversion of debt, price per share						$ 0.01
Series B Convertible Preferred Stock [Member] | Private Placement [Member]
Conversion of debt into stock			695,302
Series B Convertible Preferred Stock [Member] | Convertible Secured Debenture and Convertible Promissory [Member]
Conversion of debt, description	These shares were subject to a restriction on any sales below $0.02 through December 31, 2018 and will have volume limitations on any sales below $0.01 during the first six months of 2019.
Series B Convertible Preferred Stock [Member] | Path Forward Agreements [Member] | Convertible Secured Debenture and Convertible Promissory [Member]
Conversion of debt into stock			2,610,453
Common Stock [Member] | Private Placement [Member]
Conversion of debt into stock			287,168,409
Common Stock [Member] | Path Forward Agreements [Member]
Conversion of debt into stock		12,000,000
Conversion of debt, price per share		$ 0.014
Common Stock [Member] | Path Forward Agreements [Member] | Convertible Secured Debenture and Convertible Promissory [Member]
Conversion of debt into stock			302,339,252

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Production equipment cost	$ 2,500
Fixed assets capitalized cost	1,500
Nonrefundable fee	$ 17,500
Royalties percentage, description	The increase in royalties from one percent (1%) to two percent (2%).
Amortization estimated useful live	3 years
Economic life of the patent	10 years
Income from grants	$ 17,500
Research and development costs	104,208	$ 203,037
Advertising and marketing costs	$ 11,500	$ 111,662
Income tax description	The Act reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings.
Income tax federal corporate tax rate	21.00%
Reduction of net deferred tax assets	$ 3,300,000
Net Sales [Member]
Royalties percentage, description	The Company also agreed to increase the royalty fee on net sales from 1% to 2%.
January 2019 [Member]
Nonrefundable fee	$ 10,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Depreciation Estimated Useful Life (Details)	12 Months Ended
	Dec. 31, 2018
Production Equipment [Member] | Minimum [Member]
Estimated useful life of asset	3 years
Production Equipment [Member] | Maximum [Member]
Estimated useful life of asset	7 years
Office Equipment [Member] | Minimum [Member]
Estimated useful life of asset	2 years
Office Equipment [Member] | Maximum [Member]
Estimated useful life of asset	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Estimated useful life of asset	2 years
Furniture and Fixtures [Member] | Maximum [Member]
Estimated useful life of asset	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Future Minimum Royalties (Details)	Dec. 31, 2018USD ($)
Accounting Policies [Abstract]
2019	$ 10,000
2020	10,000
2021	25,000
2022	25,000
Total	$ 70,000

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Dilutive Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Total potential dilutive securities	631,083,455	57,343,832
Convertible Debt [Member]
Total potential dilutive securities	17,594	18,155,788
Preferred Stock [Member]
Total potential dilutive securities	356,101,920	37,786,220
Common Stock Options [Member]
Total potential dilutive securities	90,544,169	1,097,623
Common Stock Warrants [Member]
Total potential dilutive securities	184,419,772	304,201

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Depreciation expense		$ 1,473
Production Equipment, Building, Leasehold Improvements, and Office Equipment [Member]
Total Fixed assets		$ 14,594

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Net fixed assets
Production Equipment [Member]
Production equipment	15,182	15,182
Less accumulated depreciation	(15,182)	(15,182)
Net fixed assets

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Oct. 10, 2018	Aug. 09, 2018	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Oct. 31, 2018	Oct. 19, 2018	Jun. 30, 2015
Accrued interest payable				$ 58,593	$ 316,784
Note maturity date, description			May 31, 2017
Debt conversion, amount converted				$ 3,240,661
Debt conversion, shares issued				637,613,204	347,400
Related party note				$ 0	$ 383,771
Related party payables				38,610	57,297
Loss on conversion of debt				605,601	(310,086)
Rental expense				0	4,500
Shareholder and Director [Member]
Payment of rent				1,500
Rental expense				$ 0
Accounts Payable and Notes Payable [Member]
Number of common stock shares issued				3,600,000
Number of shares issued, value				$ 50,400
Loss on conversion of debt				$ 35,400
Number of warrant granted				1,800,000
Convertible Notes Payable [Member]
Interest expenses, related party				$ 29,650	$ 29,230
Series B Convertible Preferred Stock [Member]
Conversion price per share						$ 0.01
Common Stock [Member]
Number of common stock shares issued				38,662,562
Warrant to purchase of common stock				19,331,281
Accrued compensation				$ 541,276
Number of warrants issued, value				238,973
Loss on conversion of debt				$ 586,936
Series A Convertible Preferred Stock [Member]
Conversion price per share								$ 0.50
Debt conversion, shares issued				1,225,981	1,809,250
Series A Convertible Preferred Stock [Member] | CEO [Member]
Number of common stock shares issued					100,000
Accrued compensation					$ 32,308
Accrued payable					67,692
Wages valued					$ 199,690
Series A Convertible Preferred Stock [Member] | CFO [Member]
Number of common stock shares issued					83,279
Accrued compensation					$ 83,280
Wages valued					166,299
Path Forward and Restructuring Agreement [Member]
Conversion price per share		$ 0.004
Debt conversion, amount converted		$ 500,000
Path Forward and Restructuring Agreement [Member] | Series B Convertible Preferred Stock [Member]
Debt conversion, shares issued	385,302
Path Forward and Restructuring Agreement [Member] | Common Stock [Member]
Debt conversion, shares issued	50,000,000
Path Forward and Restructuring Agreement [Member] | Warrant [Member]
Debt conversion, shares issued	44,265,100
Warrant exercise price per share	$ 0.01
Related Party Note [Member]
Accrued interest payable				$ 0	$ 29,230
Old Related Party Note [Member]
Accrued interest payable				$ 1,054
Director and Major Stockholder [Member]
Accrued interest payable			$ 51,576
Director and Major Stockholder [Member] | Related Party Note [Member]
Related party transaction accrued interest rate			10.00%
Note maturity date			May 9, 2018
Note maturity date, description			The note holder agreed to an extension of the due date until May 9, 2018
Conversion price per share							$ 0.013

Related Party Transactions - S

Related Party Transactions - Schedule of Related Party Transaction (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Principal net		$ 383,771
Accrued interest		29,230
Related Party [Member]
Principal net		383,771
Accrued interest		$ 29,230

Related Party Transactions - _2

Related Party Transactions - Schedule of Related Party Transaction (Details) (Parenthetical)	1 Months Ended
	Mar. 31, 2017USD ($)
Related Party Transactions [Abstract]
Note, amount	$ 332,195
Note, interest rate	10.00%
Note due date, description	May 31, 2017

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	Oct. 30, 2018	Oct. 10, 2018	Apr. 19, 2018	Oct. 31, 2018	Jul. 31, 2018	Jun. 30, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017
Debt instrument percentage										10.00%
Proceeds from convertible note payable							$ 50,000	$ 1,230,334
Debt conversion of convertible debt							3,240,661
Accrued interest payable							58,593	316,784
Debt principal amount										$ 332,195
Payment of convertible note payable							200,000
Amortization of debt discount							$ 791,928	$ 2,023,144
Repurchase of notes			$ 228,332
Conversion of debt into stock							637,613,204	347,400
Loss on extinguishment of debt							$ 605,601	$ (310,086)
Path Forward Agreement [Member]
Debt instrument, description		These shares were subject to a restriction on any sales below $0.02 through December 31, 2018 and will have volume limitations on any sales below $0.01 during the first six months of 2019.
Path Forward Agreements [Member]
Loss on extinguishment of debt	$ 108,916
Series A Convertible Preferred Stock [Member]
Principal amount, percentage						100.00%
Conversion of debt into stock							1,225,981	1,809,250
Conversion price per share						$ 0.50
Series B Convertible Preferred Stock [Member]
Principal amount, percentage				100.00%
Conversion price per share				$ 0.01
Series B Convertible Preferred Stock [Member] | Path Forward Agreement [Member]
Conversion of debt into stock		2,610,453
Conversion price per share		$ 0.004
Common Stock [Member]
Number of shares issued							136,628,000
Loss on extinguishment of debt							$ 586,936
Common Stock [Member] | Path Forward Agreements [Member]
Debt principal amount	$ 60,000
Conversion of debt into stock	12,000,000
Conversion price per share	$ 0.014
Interest and other costs	$ 10,000
Convertible Note Payable [Member]
Interest expenses							187,741	$ 268,961
Convertible Notes [Member]
Debt instrument percentage								10.00%
Advances from shareholders								$ 137,000
Accrued interest payable								69,732
Debt principal amount								774,362
Loan fees								$ 386,758
Convertible Notes [Member] | Path Forward Agreements [Member]
Debt instrument percentage					8.00%
Debt conversion of convertible debt					$ 50,000
Capital raise					$ 500,000
Convertible Debentures [Member]
Original issue discount								7.50%
Proceeds from convertible note payable								$ 1,230,334
Debt conversion of convertible debt									$ 1,358,750
Debt principal amount								774,362
Loan fees								$ 386,758
Outstanding Notes [Member]
Loan fees							101,631
Payment of convertible note payable							322,381
Amortization of debt discount							$ 2,023,144
Outstanding Notes [Member] | Series A Convertible Preferred Stock [Member]
Number of shares issued							843,699
Increase in debt discount							$ 1,212,503
May 2017 Notes [Member]
Notes payable							3,136,506
Debt discount							$ 2,419,240
Principal amount, percentage							130.00%
November 2017 Notes [Member]
Notes payable							$ 166,666
Debt discount							$ 92,004
Convertible Secured Debentures and Convertible Promissory Note [Member] | Path Forward Agreement [Member]
Debt conversion of convertible debt		$ 2,253,538
Conversion of debt into stock		302,339,252

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Principal (net)	$ 53,824	$ 2,563,272
Accrued Interest	58,593	316,784
Penalties on notes past due principal (net)	8,824	7,028
Penalties on notes in default accrued interest
Convertible Notes Payable One [Member]
Principal (net)	45,000	45,000
Accrued Interest	34,603	29,218
Convertible Notes Payable Two [Member]
Principal (net)
Accrued Interest	17,341	17,341
Convertible Notes Payable Three [Member]
Principal (net)
Accrued Interest	5,953	5,953
Convertible Notes Payable Four [Member]
Principal (net)
Accrued Interest	696	696
Convertible Notes Payable Five [Member]
Principal (net)		1,833,310
Accrued Interest		178,304
Convertible Notes Payable Six [Member]
Principal (net)		500,703
Accrued Interest		52,831
Convertible Notes Payable Seven [Member]
Principal (net)		85,227
Accrued Interest		15,773
Convertible Notes Payable Eight [Member]
Principal (net)		92,004
Accrued Interest		$ 16,667

Convertible Notes Payable - S_2

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Debt principal amount			$ 332,195
Convertible Notes Payable One [Member]
Debt principal amount	$ 1,060,000
Debt conversion price per share	$ 4.60
Debt interest rate	12.00%
Debt maturity date description	December 2013 and January 2014
Convertible Notes Payable Two [Member]
Debt principal amount	$ 605,000
Debt conversion price per share	$ 1
Debt maturity date description	September 30, 2015
Convertible Notes Payable Two [Member] | Minimum [Member]
Debt interest rate	8.00%
Convertible Notes Payable Two [Member] | Maximum [Member]
Debt interest rate	10.00%
Convertible Notes Payable Three [Member]
Debt principal amount	$ 613,000
Debt conversion price per share	$ 1
Debt interest rate	8.00%
Debt maturity date description	June 30, 2016
Debt discount	$ 0	$ 560,913
Convertible Notes Payable Four [Member]
Debt principal amount	$ 345,000
Debt conversion price per share	$ 1
Debt interest rate	8.00%
Debt maturity date description	June 30, 2016
Convertible Notes Payable Five [Member]
Debt principal amount	$ 2,378,155
Debt conversion price per share	$ 0.20
Debt interest rate	7.50%
Debt maturity date description	May 2018
Debt discount	$ 0	544,845
Convertible Notes Payable Six [Member]
Debt principal amount	$ 820,420
Debt conversion price per share	$ 0.12
Debt interest rate	7.50%
Debt maturity date description	May 2018
Debt discount	$ 0	147,335
Convertible Notes Payable Seven [Member]
Debt principal amount	$ 110,312
Debt conversion price per share	$ 0.13
Debt interest rate	7.50%
Debt maturity date description	May 2018
Debt discount	$ 0	25,085
Convertible Notes Payable Eight [Member]
Debt principal amount	$ 166,666
Debt conversion price per share	$ 0.12
Debt interest rate	10.00%
Debt maturity date description	April 15, 2018
Debt discount	$ 0	$ 74,662

Derivative Liability - Schedule

Derivative Liability - Schedule of Derivative Liability Account Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Derivative liability Beginning Balance		$ 324,532
Derivative Liability Recorded on New Instruments	4,636,517	99,661
Elimination of Liability on Conversion	(4,217,762)
(Gain) on Settlement of Debt	(605,601)	(15,704)
Change in Fair Value	186,846	(408,489)
Derivative liability, ending balance
Warrant [Member]
Derivative liability Beginning Balance		58
Derivative Liability Recorded on New Instruments
Elimination of Liability on Conversion
(Gain) on Settlement of Debt
Change in Fair Value		(58)
Derivative liability, ending balance
Conversion Feature [Member]
Derivative liability Beginning Balance		324,474
Derivative Liability Recorded on New Instruments	4,636,517	99,661
Elimination of Liability on Conversion	(4,217,762)
(Gain) on Settlement of Debt	(605,601)	(15,704)
Change in Fair Value	186,846	(408,431)
Derivative liability, ending balance

Derivative Liability - Schedu_2

Derivative Liability - Schedule of Assumptions for Fair Value Determination (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Warrant [Member] | Risk-free Interest Rate [Member]
Fair value assumptions, percentage	0.00%	1.39%
Warrant [Member] | Expected Life in Years [Member]
Fair value assumption, expected term	0 years	2 months 30 days
Warrant [Member] | Dividend Yield [Member]
Fair value assumptions, percentage	0.00%	0.00%
Warrant [Member] | Expected Volatility [Member]
Fair value assumptions, percentage	0.00%	187.59%
Conversion Feature [Member] | Risk-free Interest Rate [Member]
Fair value assumptions, percentage		0.00%
Conversion Feature [Member] | Risk-free Interest Rate [Member] | Minimum [Member]
Fair value assumptions, percentage	1.62%
Conversion Feature [Member] | Risk-free Interest Rate [Member] | Maximum [Member]
Fair value assumptions, percentage	2.59%
Conversion Feature [Member] | Expected Life in Years [Member]
Fair value assumption, expected term		0 years
Conversion Feature [Member] | Expected Life in Years [Member] | Minimum [Member]
Fair value assumption, expected term	1 month 9 days
Conversion Feature [Member] | Expected Life in Years [Member] | Maximum [Member]
Fair value assumption, expected term	1 year 1 month 6 days
Conversion Feature [Member] | Dividend Yield [Member]
Fair value assumptions, percentage	0.00%	0.00%
Conversion Feature [Member] | Expected Volatility [Member]
Fair value assumptions, percentage		0.00%
Conversion Feature [Member] | Expected Volatility [Member] | Minimum [Member]
Fair value assumptions, percentage	174.46%
Conversion Feature [Member] | Expected Volatility [Member] | Maximum [Member]
Fair value assumptions, percentage	519.42%

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2018USD ($)
Income Tax Disclosure [Abstract]
Income tax description	The Act reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings.
US federal corporate tax rate	21.00%
Reduction of net deferred tax assets	$ 3,300,000
Net operating loss carryforwards	$ 27,408,300
Net operating loss carryforwards expiration date description	Year 2018 through 2037

Income Taxes - Schedule of Net

Income Taxes - Schedule of Net Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Net operating loss carryover	$ 5,760,000	$ 5,640,000
Deferred tax assets, Depreciation
Related party accrual	2,300	110,600
Capital Loss Carryover	3,400	3,400
Deferred tax liabilities, Depreciation	(2,100)	(2,100)
Valuation allowance	(5,763,600)	(5,751,900)
Net deferred tax asset

Income Taxes - Schedule of Fede

Income Taxes - Schedule of Federal Income Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Book income (loss)	$ (1,617,600)	$ (1,347,900)
Grant income
Depreciation	(1,100)	(700)
Intangible asset impairment
Related party accrual	(108,300)	(100)
Meals and entertainment	300	200
Stock for services	100	130,300
Options expense	302,000	142,600
Non-cash interest expense	1,046,900	946,500
Other non-deductible expenses	261,800	(12,200)
Valuation allowance	115,900	141,300
Income tax expense

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Oct. 31, 2018	Jun. 30, 2015	Dec. 31, 2018	Dec. 31, 2017	Oct. 08, 2018	Mar. 31, 2016
Common stock shares authorized			2,000,000,000	2,000,000,000
Common stock par value			$ 0.001	$ 0.001
Common stock shares issued			1,307,565,888	65,695,213
Common stock shares outstanding			1,307,565,888	65,695,213
Preferred stock shares authorized			20,000,000	20,000,000
Preferred stock par value			$ 0.001	$ 0.001
Number of stock issued for services, value			$ 449	$ 254,438
Gain on extinguishment of debt			35,217
Number of shares issued, value			738,140
Stock issued during period for conversion of shares, value
Conversion of debt, shares			637,613,204	347,400
Preferred stock issued for cash, value				$ 2,701,153
Stock based compensation			$ 1,164,885	103,865
Expenses related to vesting of RSU's			113,189	$ 575,011
Expenses related to RSU's not yet vested			$ 155,400
Warrant [Member]
Warrants to settle accrued payroll			19,331,281
Warrants to settle other payables			63,404,024
Warrants to settle accounts payable			21,800,000
Warrants issued for consulting services			6,000,000
Warrants issuance of shares issued for cash			73,814,000
Common Stock [Member]
Number of stock issued for services			10,000	2,302,194
Number of stock issued for services, value			$ 10	$ 2,302
Number of shares issued, value			$ 136,628
Stock issued during period for conversion of shares, shares			12,259,810	18,692,500
Stock issued during period for conversion of shares, value			$ 12,260	$ 18,693
Number of shares issued			136,628,000
Preferred stock issued for cash, value
Officers and Consultants [Member]
Gain on extinguishment of debt			$ 1,256,972
Number of common stock for accrued compensation, value			1,665,285
Third Party and Former Employees [Member]
Gain on extinguishment of debt				294,530
Accrued payroll				272,164
Accounts payable				$ 205,283
Third Party and Former Employees [Member] | Common Stock [Member]
Number of shares issued				3,096,483
Settlement of Debt [Member]
Settlement and conversion of debt				3,040,239
Settlement and conversion of debt, value			3,545,378	$ 322,381
Convertible debt instrument accrued interest			506,245	36,479
Derivative liabilities			4,823,363
Gain on extinguishment of debt			$ 1,694,005	21,282
Number of shares issued, value				334,048
Debt discount				159,299
Additional paid in capital				$ 113,205
Series B Convertible Preferred Stock [Member]
Preferred stock shares authorized	5,000,000		5,000,000	0	5,000,000
Preferred stock par value					$ 0.001
Preferred stock, liquidation preference per share	$ 1
Conversion price per share	$ 0.01
Voting percentage	Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100% of the Liquidation Preference.
Redemption percentage	100.00%
Number of stock issued for services
Settlement and conversion of debt			2,995,755
Preferred stock issued for cash			110,000
Preferred stock issued for cash, value			$ 55,000
Stock issued for exercise of warrants, shares
Preferred stock issued for warrants surrendered
Preferred stock issued for loan fees, shares
Series B Convertible Preferred Stock [Member] | Officers and Consultants [Member]
Number of common stock for accrued compensation			$ 200,000
Series A Convertible Preferred Stock [Member]
Preferred stock shares authorized		2,500,000	5,000,000	5,000,000		2,500,000
Preferred stock, liquidation preference per share		$ 5
Conversion price per share		$ 0.50
Gross proceeds from preferred stock		$ 5,000,000
Voting percentage		Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference.
Redemption percentage		100.00%
Number of stock issued for services
Debt discount				$ 1,212,503
Stock issued during period for conversion of shares, shares			12,259,810	18,692,500
Stock issued during period for conversion of shares, value			$ 4,678,380	$ 4,305,962
Conversion of debt, shares			1,225,981	1,809,250
Preferred stock issued for cash
Stock issued for exercise of warrants, shares
Preferred stock issued for warrants surrendered
Preferred stock issued for loan fees, shares				843,699
Preferred stock issued for loan fees				$ 1,212,503
Series A Convertible Preferred Stock [Member] | Note Holders [Member]
Number of shares issued, value				$ 1,488,650
Number of shares issued				627,302
Conversion date description				December 15, 2017 to May 9, 2018
Series A Convertible Preferred Stock [Member] | CEO and CFO [Member]
Number of shares issued				183,279
Accrued payroll				$ 115,587
Accounts payable				67,692
Wages				$ 365,989
Series A Convertible Preferred Stock [Member] | Third Party and Former Employees [Member]
Number of shares issued				160,000
Series A Convertible Preferred Stock [Member] | Maximum [Member]
Preferred stock shares authorized						5,000,000
Common Stock [Member]
Number of stock issued for services			10,000	2,302,194
Number of stock issued for services, value			$ 449	$ 254,438
Settlement and conversion of debt			1,028,230,303
Number of shares issued, value			$ 683,140
Number of shares issued			136,628,000
Common Stock [Member] | Officers and Consultants [Member]
Number of common stock for accrued compensation			$ 62,262,562

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Changes in Stock Option (Details) - Stock Options - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Shares Options Outstanding Beginning Balance	1,222,500	2,402,500
Number of Options granted	89,321,669
Number of Options exercised
Number of Options expired		(1,180,000)
Number of Shares Options Outstanding Ending Balance	90,544,169	1,222,500
Number of Shares Options Exercisable	90,544,169
Weighted Average Exercise Price granted	$ 0.014
Weighted Average Exercise Price exercised
Weighted Average Exercise Price expired
Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning	2 years 10 months 28 days	3 years 10 months 28 days
Weighted Average Remaining Contractual Life (in years) Outstanding, Ending	6 years 9 months	2 years 10 months 28 days
Weighted Average Remaining Contractual Life (in years) Exercisable	6 years 9 months
Aggregate Intrinsic Value Outstanding Beginning
Aggregate Intrinsic Value Outstanding Ending
Aggregate Intrinsic Value Exercisable
Weighted Average Exercise Price Per Share Outstanding Beginning	$ 1.08	$ 0.81
Weighted Average Exercise Price Per Share Options granted
Weighted Average Exercise Price Per Share Options exercised
Weighted Average Exercise Price Per Share Options expired
Weighted Average Exercise Price Per Share Outstanding Ending	0.03	1.08
Weighted Average Exercise Price Per Share Exercisable	0.03
Minimum [Member]
Weighted Average Exercise Price Outstanding Beginning Balance	0.50	0.50
Weighted Average Exercise Price exercised
Weighted Average Exercise Price expired		0.12
Weighted Average Exercise Price Outstanding Ending Balance	0.014	0.50
Exercise Price Per Share Exercisable	0.014
Maximum [Member]
Weighted Average Exercise Price Outstanding Beginning Balance	15	15
Weighted Average Exercise Price exercised
Weighted Average Exercise Price expired		0.15
Weighted Average Exercise Price Outstanding Ending Balance	15	$ 15
Exercise Price Per Share Exercisable	$ 15

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Changes in Stock Warrants (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Shares, Warrants Outstanding Beginning	304,200	3,579,505
Number of Shares, Warrants granted	184,349,305
Number of Shares, Warrants exercised
Number of Shares, Warrants expired/cancelled	(233,733)	(3,275,305)
Number of Shares, Warrants Outstanding Ending	184,419,772	304,200
Number of Shares, Warrants Exercisable Ending	184,419,772
Weighted Average Exercise Price Outstanding	$ 1.19
Exercise Price Per Share Warrants granted	0.01
Exercise Price Per Share Warrants exercised
Exercise Price Per Share Warrants expired/cancelled	0.40	4.62
Weighted Average Exercise Price Outstanding	0.01	$ 1.19
Exercise Price Per Share Exercisable	$ 0.01
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning	1 year 2 months 8 days	1 year 10 months 25 days
Weighted Average Remaining Contractual Life Warrants Outstanding Ending	1 year 9 months 7 days	1 year 2 months 8 days
Weighted Average Remaining Contractual Life Warrants Exercisable	1 year 9 months 7 days
Aggregate Intrinsic Value Outstanding Beginning	$ 749	$ 2,052,699
Aggregate Intrinsic Value Outstanding Ending		$ 749
Aggregate Intrinsic Value Exercisable
Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning	$ 2.63	$ 4.45
Weighted Average Exercise Price Per Share Exercise Price Warrants granted
Weighted Average Exercise Price Per Share Exercise Price Warrants exercised
Weighted Average Exercise Price Per Share Exercise Price Warrants expired/cancelled
Weighted Average Exercise Price Per Share Exercise Price Warrants Ending	0.01	2.63
Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable	0.01
Minimum [Member]
Weighted Average Exercise Price Outstanding		0.1
Exercise Price Per Share Warrants granted
Exercise Price Per Share Warrants exercised
Exercise Price Per Share Warrants expired/cancelled
Weighted Average Exercise Price Outstanding
Maximum [Member]
Weighted Average Exercise Price Outstanding		10
Exercise Price Per Share Warrants granted
Exercise Price Per Share Warrants exercised
Exercise Price Per Share Warrants expired/cancelled
Weighted Average Exercise Price Outstanding

Stockholders' Deficit - Sched_3

Stockholders' Deficit - Schedule of Changes in Restricted Stock Units (Details) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Shares, RSU's Outstanding Beginning	5,740,000
Number of Shares, RSU's Granted		12,560,000
Number of Shares, RSU's Vested	(2,480,000)	(6,820,000)
Number of Shares, RSU's Forfeited	(1,160,000)
Number of Shares, RSU's Outstanding Ending	2,100,000	5,740,000
Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning	$ 0.07
Weighted Average Grant Date Fair Value, RSU's Granted	0.07	0.07
Weighted Average Grant Date Fair Value, RSU's Vested
Weighted Average Grant Date Fair Value, RSU's Forfeited
Weighted Average Grant Date Fair Value, RSU's Outstanding Ending	$ 0.07	$ 0.07

Concentrations of Credit and _2

Concentrations of Credit and Other Risks (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Allowance for doubtful accounts receivable
Customer One[Member]
Accounts receivable
Customer One[Member] | Revenue [Member]
Concentration risk percentage	100.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Feb. 28, 2019	Mar. 31, 2017
Proceeds from equity financing		$ 55,000
Debt instrument interest rate					10.00%
Common stock, shares authorized		2,000,000,000	2,000,000,000
Common Stock [Member]
Number of stock issued during period		136,628,000
Warrant [Member]
Warrant issuance shares		73,814,000
Common Stock [Member]
Number of stock issued during period		136,628,000
Warrant issuance value		$ 238,973
Subsequent Event [Member]
Common stock, shares authorized	950,000,000
Subsequent Event [Member] | Common Stock [Member]
Number of stock issued during period	52,421,800
Subsequent Event [Member] | One Year 8% Promissory Note [Member]
Debt instrument interest rate	8.00%
Due to related parties	$ 60,000
Subsequent Event [Member] | Two Six-month 8% Promissory Note [Member]
Debt instrument interest rate				8.00%
Warrant issuance value				$ 100,000
Warrant issuance shares				10,000,000
Warrant term				2 years
Subsequent Event [Member] | Series B Convertible Preferred Stock [Member]
Number of shares issued upon conversion	524,218
Subsequent Event [Member] | Accredited Investors [Member]
Proceeds from equity financing	$ 100,000
Subsequent Event [Member] | Accredited Investors [Member] | Warrant [Member]
Number of stock issued during period	10,000,000
Subsequent Event [Member] | Accredited Investors [Member] | Common Stock [Member]
Number of stock issued during period	10,000,000
Subsequent Event [Member] | Accredited Investors [Member] | Series B Convertible Preferred Stock [Member]
Number of stock issued during period	100,000
Subsequent Event [Member] | Consultants [Member] | Warrant [Member]
Warrant issuance shares				675,000
Subsequent Event [Member] | Board of Directors [Member]
Reverse split	Reverse split the Company's shares of common stock on a 1 for 8 basis